Several of Florida’s coastal military installations suffer from shoreline erosion and storm damage. Currently, there are limited options to address such damages, and pursuing funding through the formal military construction process can often take several years before...
NOTICIAS
Últimas Noticias
Next Week: Rubio Staff Hosts Mobile Office Hours
U.S. Senator Marco Rubio’s (R-FL) office will host in-person and virtual Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of...
Rubio Introduces Bill to Strengthen U.S.-Philippine Security Partnership
Sovereign nations in the Indo-Pacific region have been facing increased threats from the Chinese Communist Party as it continues its expansive military strategies. One such nation is the Philippines—a U.S. treaty ally. The U.S. must firmly stand with Manilla to ...
Rubio, Warner, Colleagues Introduce Bill to Ensure a Diverse and Secure Supply of Critical Minerals
Critical minerals are crucial for our national security as they play vital roles in military equipment, defense systems, and emerging technologies. However, Communist China currently dominates the mining, processing, and manufacturing of the majority of these...
Rubio Introduces Bill to Destroy China Monopoly on Critical Minerals
The Chinese Communist Party’s industrial monopoly on critical mineral-intensive goods is a national security vulnerability. To reduce China’s leverage, the U.S., its allies, and partners must break free from supply chains relying on Chinese minerals. U.S....
Rubio, Risch, Stefanik Introduce Military Moms Act
New mothers serving in the military and dependents of service members, have expressed difficulty navigating maternal and infant health resources and services through TRICARE, the military’s health care system. Every mother should feel supported and be able to access...
Transcript: Rubio Forces NIH to Admit There Is No Conclusive Safety Data on the Impact of Puberty Blockers on Youth
Washington, D.C. — U.S. Senator Marco Rubio (R-FL) questioned Dr. Lawrence Tabak, Acting Director of the National Institutes of Health, during a Senate Appropriations Subcommittee on Labor, Health and Human Services hearing. Tabak acknowledged there are no long-term studies on the risks associated with the off-label use of puberty blockers by minors.
A video of Rubio’s questioning can be found here and a transcript of the exchange is below.
RUBIO: Dr. Tabak, let me start with this question. We’ve recently seen…that the Biden Administration and others in the policy realm have been actively promoting and supporting the use of things like puberty blockers and hormone therapy for young boys and girls.
I want to limit my question to minors for what they have termed “gender transforming care.” That’s not an FDA-approved use for puberty blockers and hormone therapy, I don’t believe, in any people, but especially in minors. So, as the NIH is America’s medical research agency, what work have we done at NIH… to determine if this non FDA-approved use of these medicines, this off-label use of these medicines, is appropriate for minors seeking gender transforming care?
TABAK: So, NIH funds a small number of observational studies to gather the data on the effects of treatments that transgender youth and their parents have chosen. And there are also a small number of studies that describe the health issues and risks, including HIV, that are unique to to these transgender youth. But all of the research in this space is observational. We do no interventional work.
RUBIO: I guess my question is…[it’s] one thing i[f] a decision [is] made by an adult, right? And, especially given the irreversible nature of some of these treatments, isn’t there some wisdom in the notion that, before policymakers are out there promoting the off-label use of medications that lead to permanent changes, that there be some more research done on [the] impact [it will have] five, ten, 15, 20 years from now?
TABAK: So, as you know, transgender youth are more vulnerable to depression, anxiety, [engagement] in self-harm. And so it is important that we examine and evaluate the potential effects of these treatments. Researchers are observing longer-term psychological impact of these protocols. And so by by looking at individuals, transgender youth with and without histories of puberty suppression, we will be able to better answer the types of questions that you’re posing.
RUBIO: Yeah, I guess that’s my point. My point is, we don’t know what its long term implications are when we weigh the cost and the benefits. The FDA hasn’t approved this and yet we have policymakers promoting it, and I think that’s an important point.
We clearly don’t want anybody harming themselves…but…these policy decisions are being made on the basis of observational guidance and, by your own admission, without any sort of long term trajectory on its holistic impact.